177946-33-7

Upstream product

• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 100-52-7 benzaldehyde 
• 177948-04-8 4-Aminomethyl-4-hydroxy-1-[3-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]propyl]piperidine 
• 177948-03-7 {4-hydroxy-1-[3-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-propyl]-piperidin-4-ylmethyl}-carbamic acid tert-butyl ester 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 
• 177948-02-6 4-[(t-butoxycarbonylamino)methyl]-4-hydroxypiperidine 
• 174609-75-7 methanesulfonic acid 3-(5-[1,2,4]triazol-4-yl-1H-indol-3-yl)-propyl ester 
• 177948-00-4 3-(5-[1,2,4-triazol-4-yl]-1H-indol-3-yl)propan-1-ol 

Relevant academic research and scientific papers

4-hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidines: Selective h5-HT(1D) agonists for the treatment of migraine

A series of 4-hydroxy-l-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl] piperidines was investigated as potential selective h5-HT(1D) agonists for the treatment of migraine. The 4-[(N-benzyl-N-methyl)amino]methyl analog 12a was found to be a full agonist

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.